home / stock / albo / albo news

ALBO News and Press, Albireo Pharma Inc. From 11/06/19

Stock Information
Company Name: Albireo Pharma Inc.
Stock Symbol: ALBO
Market: NASDAQ
Menu
ALBO ALBO Quote ALBO Short ALBO News ALBO Articles ALBO Message Board
Get ALBO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALBO - Albireo Reports Third Quarter 2019 Financial Results and Provides Business Update

—  Phase 3 PFIC trial randomization more than three-quarters complete. — — Topline results expected mid-2020. — — Pivotal trial in biliary atresia expected to be initiated in 2020.   — — Management to host conference ca...
ALBO - Albireo Appoints Michelle Graham as Chief Human Resources Officer

BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Michelle Graham has been appointed Chief Human Resources Officer, effective today. She will...

ALBO - Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019

BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on Nove...

ALBO - Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families

BOSTON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today its support for PFIC Awareness Day, and reaffirmed its commitment to patients and families living wit...
ALBO - Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting

BOSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced upcoming presentations at the North American Society for Pediatric Gastroenterology, Hepatology and ...

ALBO - Albireo to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present at the 21 st Annual Rodman &...

ALBO - Alberio Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2019 Results - Earnings Call Transcript

Alberio Pharma, Inc. (ALBO) Q2 2019 Results Conference Call August 8, 2019 10:00 AM ET Company Participants Paul Arndt - Investor Relations and Corporate Communications Executive Ron Cooper - President and Chief Executive Officer Simon Harford - Chief Financial Officer Pat Horn...
ALBO - Albireo Pharma EPS beats by $0.08, beats on revenue

Albireo Pharma (NASDAQ: ALBO ): Q2 GAAP EPS of -$1.35 beats by $0.08 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ALBO - Albireo Reports Second Quarter 2019 Financial Results

— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON, Aug. 08, 2019 (GLOBE NEWSWIR...

ALBO - Albireo to Present at Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Wedbush PacGrow...
Previous 10 Next 10